70 Multicenter Trial of Rivaroxaban for Early Discharge of Pulmonary Embolism from the Emergency Department

Hospitalization after an ED diagnosis of a pulmonary embolism (PE) is common, expensive, and of questionable clinical benefit in low-risk patients. Our purpose was to determine if low-risk PE patients, discharged home from the ED on rivaroxaban, have a different total number of hospital days through day 30 vs standard of care (SOC). This was a multicenter, prospective, open label, randomized clinical trial of patients ≥18 years of age with an ED...